Clinical Report: FDA approves first therapy for warm autoimmune hemolytic anemia
Overview
The FDA has approved nipocalimab-aahu (IMAAVY) as the first therapy for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older. This approval is based on the results of the phase 2/3 ENERGY trial, which demonstrated efficacy in improving hemoglobin levels compared to placebo.
Background
Warm autoimmune hemolytic anemia (wAIHA) is characterized by the destruction of red blood cells due to autoantibodies, leading to anemia and increased risk of complications.
Data Highlights
| Group | Durable Hemoglobin Response | Mean Hemoglobin Change at Week 1 | Mean Change in Fatigue Score at Week 24 |
|---|---|---|---|
| Nipocalimab 30 mg/kg | 23.7% (9/38) | 1 g/dL | 3.5 points |
| Nipocalimab 15 mg/kg | 21.1% (8/38) | - | - |
| Placebo | 7.7% (3/39) | - | - |
Key Findings
- Nipocalimab-aahu is the first FDA-approved therapy specifically for wAIHA.
- The approval was based on the phase 2/3 ENERGY trial involving 115 adults.
- Participants receiving nipocalimab had a significantly higher durable hemoglobin response compared to placebo.
- Mean hemoglobin levels increased by 1 g/dL at week 1 for the 30 mg/kg dose group.
- Common adverse reactions included peripheral edema, diarrhea, and fever.
Clinical Implications
Clinicians should be aware of the potential adverse effects and monitor patients accordingly.
Conclusion
The approval of nipocalimab represents a milestone in the management of warm autoimmune hemolytic anemia.
Related Resources & Content
- Johnson & Johnson, Investor News, 2026 -- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA)
- Johnson & Johnson, JNJ Medical Connect, 2026 -- Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized trial
- MDSpire News — FDA Approves Treg Cell Therapy
- the asco post — FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
- the medicine maker — This Week's CGT News: First Treg Therapy Approved
- The ASCO Post — FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients | Johnson & Johnson
- https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/eha/nipocalimab-for-warm-autoimmune-hemolytic-anemia-results-from-the-phase-23-rando.pdf
- Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
